We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Allogene Therapeutics (ALLO - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Allogene Therapeutics is a member of the Medical sector. This group includes 931 individual stocks and currently holds a Zacks Sector Rank of #9. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Allogene Therapeutics is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ALLO's full-year earnings has moved 3% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, ALLO has returned 25.6% so far this year. Meanwhile, stocks in the Medical group have gained about 7.7% on average. This shows that Allogene Therapeutics is outperforming its peers so far this year.
Alzamend Neuro, Inc. (ALZN - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 20.9%.
Over the past three months, Alzamend Neuro, Inc.'s consensus EPS estimate for the current year has increased 29%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Allogene Therapeutics belongs to the Medical - Biomedical and Genetics industry, which includes 452 individual stocks and currently sits at #87 in the Zacks Industry Rank. On average, stocks in this group have gained 21.4% this year, meaning that ALLO is performing better in terms of year-to-date returns. Alzamend Neuro, Inc. is also part of the same industry.
Investors interested in the Medical sector may want to keep a close eye on Allogene Therapeutics and Alzamend Neuro, Inc. as they attempt to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Allogene Therapeutics (ALLO) Stock Outpacing Its Medical Peers This Year?
Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Allogene Therapeutics (ALLO - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Allogene Therapeutics is a member of the Medical sector. This group includes 931 individual stocks and currently holds a Zacks Sector Rank of #9. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Allogene Therapeutics is currently sporting a Zacks Rank of #2 (Buy).
Within the past quarter, the Zacks Consensus Estimate for ALLO's full-year earnings has moved 3% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, ALLO has returned 25.6% so far this year. Meanwhile, stocks in the Medical group have gained about 7.7% on average. This shows that Allogene Therapeutics is outperforming its peers so far this year.
Alzamend Neuro, Inc. (ALZN - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 20.9%.
Over the past three months, Alzamend Neuro, Inc.'s consensus EPS estimate for the current year has increased 29%. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Allogene Therapeutics belongs to the Medical - Biomedical and Genetics industry, which includes 452 individual stocks and currently sits at #87 in the Zacks Industry Rank. On average, stocks in this group have gained 21.4% this year, meaning that ALLO is performing better in terms of year-to-date returns. Alzamend Neuro, Inc. is also part of the same industry.
Investors interested in the Medical sector may want to keep a close eye on Allogene Therapeutics and Alzamend Neuro, Inc. as they attempt to continue their solid performance.